TherapeuticsMD Stock Forecast

Stock Price Forecast

There have not been any analyst price target forecasts for TherapeuticsMD in the last 12 months.

Price Target: n/a

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for TherapeuticsMD.

Recommendation Trends

Rating	Mar '23	Apr '23	May '23	Jun '23	Jul '23
Strong Buy	0	0	0	0	0
Buy	0	0	0	0	0
Hold	2	2	2	2	2
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $5	Hold	Reiterates	$5	+143.90%	Aug 17, 2023
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Initiates $5	Hold	Initiates	$5	+143.90%	Jan 11, 2023
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $1	Hold	Reiterates	$1	-51.22%	Jul 13, 2022
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades $10	Strong Buy → Hold	Downgrades	$10	+387.80%	Jun 7, 2022
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Buy → Hold Downgrades $250 → $50	Buy → Hold	Downgrades	$250 → $50	+2,339.02%	May 6, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 3.02M

Revenue Next Year

n/a

EPS This Year

n/a

from -0.05

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	2.57M	69.96M	1.30M	1.76M	3.02M
Revenue Growth	-96.03%	2,619.12%	-98.14%	35.25%	71.61%
EPS	-21.66	11.95	-0.99	-0.19	-0.05
EPS Growth	-	-	-	-	-
Forward PE	-	-	-	-	-
No. Analysts	-	-	-	-	-

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.